Evidence map›Paper›PMID 37581105›Full record

ArticleTherapeutic advances in infectious disease

The hidden cost of dalbavancin: OPAT RN time required in coordination for persons who use drugs.

Alyse H Douglass, Heather Mayer, Kathleen Young, Monica K Sikka, Luke Strnad, Jina Makadia, Ellie Sukerman, James S Lewis, Amber C Streifel

Open access · goldAbstract read
In one paragraph

Article in Therapeutic advances in infectious disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 4 citations in OpenAlex.

  1. Trial
  2. Review
  3. Management of outpatient parenteral antibiotic therapy: a United States-based multi-center survey.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2026
    Article
  4. A bundle of the top 10 OPAT publications in 2024.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2026
    Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Alyse H DouglassDivision of Infectious Diseases, Department of Medicine, Oregon Health & Science University, Portland, OR, USA.
Heather MayerDivision of Infectious Diseases, Department of Medicine, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA.ORCID https://orcid.org/0009-0000-3200-352X
Kathleen YoungDivision of Infectious Diseases, Department of Medicine, Oregon Health & Science University, Portland, OR, USA.
Monica K SikkaDivision of Infectious Diseases, Department of Medicine, Oregon Health & Science University, Portland, OR, USA.ORCID https://orcid.org/0000-0001-8192-8019
Luke StrnadSchool of Public Health, Epidemiology Programs, School of Public Health, Epidemiology Programs, Oregon Health & Science University and Portland State University, Portland, OR, USA.
Jina MakadiaDivision of Infectious Diseases, Department of Medicine, Oregon Health & Science University, Portland, OR, USA.
Ellie SukermanDivision of Infectious Diseases, Department of Medicine, Oregon Health & Science University, Portland, OR, USA.
James S LewisDepartment of Pharmacy, Oregon Health & Science University, Portland, OR, USA.
Amber C StreifelDepartment of Pharmacy, Oregon Health & Science University, Portland, OR, USA.
Oregon Health & Science University · USPortland State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Serious infections in persons who use drugs (PWUD) are rising. Dalbavancin, due to its extended half-life, offers an alternative treatment for patients in whom standard of care antibiotics are not feasible or practical, allowing for reduced hospital days and the avoidance of central line placement or the use of complex oral regimens. Objectives: We aim to describe the time and effort required for coordination of dalbavancin courses by outpatient registered nurses (RNs) and other outpatient parenteral antimicrobial therapy (OPAT) staff. Design and methods: We conducted a retrospective review of adult patients with documented substance use who received at least one dose of dalbavancin and quantified the number of interventions required by our OPAT RNs and other OPAT staff for coordination of dalbavancin courses. Additionally, detailed data on time spent per intervention were prospectively collected for a 1-month period. Results: A total of 52 patients with 53 dalbavancin courses were included. Most substance use was intravenous. Infectious diagnoses included bone and joint infections (61%) and endocarditis (7%), in addition to skin and soft tissue infections (19%). Infections were most commonly caused by Conclusions: The ease of dalbavancin administration does not eliminate the need for extensive RN coordination for successful administration of doses in the outpatient setting for PWUD. This need should be accounted for in program staffing to help increase successful dalbavancin course completion.

Indexed as

dalbavancin/long-acting glycopeptidesnurse coordinatoroutpatient parenteral antimicrobial therapyPWUD

Identifiers

PMID37581105
PMCPMC10423448
OpenAlexW4385785216

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.